RICHMOND, Va., March 6, 2001 (PRIMEZONE) -- Healthcare companies will discuss prospects and strategies at the Healthcare Stocks Forum on Wednesday, March 13. This virtual Forum, free to investors, is accessible over the Internet via www.informedinvestors.com from 9:30 a.m.-11:00 a.m. EST. Investors have the opportunity to hear directly from company executives and get their investment information straight from the source.
The Informed Investors Forum will have senior executives from Biomira, Inc. (Nasdaq:BIOM) and BioTransplant Incorporated (Nasdaq:BTRN) speaking for approximately 30 minutes each with PowerPoint presentations. Investors are invited to email questions to executives. The forum will also be archived on www.informedinvestors.com, www.vcall.com and www.investorconference.com.
The keynote address will be delivered by Harry Ostrer M.D. Dr. Ostrer is Director of the Human Genetics Program of the Department of Pediatrics at New York University School of Medicine, and he is Co-Chair of the Genetics Curriculum Advisory Committee. He specializes in Human Genetics and Genetic Susceptibility to Disease. He will provide valuable insight which can help investors capitalize on medical advances.
Biomira is a biotechnology company specializing in the development of innovative therapeutic approaches to cancer management. In addition to completion of the multinational Phase III trial with THERATOPE(r) vaccine for the treatment of metastatic breast cancer, and a Phase II pilot study of THERATOPE(r) vaccine in colorectal cancer, Biomira is developing a portfolio of complementary vaccine candidates, including BLP25 vaccine, which is undergoing a 166-patient Phase IIb study in patients with metastatic lung cancer and a Phase II pilot study in patients with prostate cancer. Biomira's commitment to the treatment of cancer currently focuses on the development of synthetic vaccines and novel strategies for cancer immunotherapy.
BioTransplant Incorporated is developing a portfolio of products for application in a range of medical conditions, including treatment of cancer and autoimmune diseases and organ and tissue transplantation, for which current therapies are inadequate. Siplizumab (MEDI-507), a lead product we exclusively licensed to MedImmune, is in extensive Phase II clinical trials for the treatment of psoriasis. In addition the Company is developing the AlloMune system to treat a variety of hematologic malignancies, and markets the Eligix family of cell separation products for use in bone marrow transplants.
Informed Investors is the leading producer of online and offline industry-specific investment conferences for individual investors and a member of the World Investor Link family of companies serving self-reliant investors.
About World Investor Link: Since 1992, World Investor Link (www.worldinvestorlink.com) has opened information channels between public companies and potential investors. This year World Investor Link will make more than 5 million investor introductions to over 4,600 corporate clients through services including The Annual Reports Service, The Fund Info Service, Vcall (www.vcall.com) Investor Conference (www.investorconference.com) and Informed Investors Forums (www.informedinvestors.com). These services provide investors free access to onsite and Webcast investor events and company financial reports through World Investor Link's relationships with over 204 leading financial media channels including The Wall Street Journal, Financial Times, Barron's and Yahoo!Finance. For companies and mutual funds, these services enable compliance with regulation fair-disclosure requirements and provide visibility with investors at the precise point investors are making decisions. World Investor Link, Inc., a wholly owned subsidiary of WILink.com plc (WLK on The London Stock Exchange), began operations in Richmond, Va. in 1993.